NAD+ Injections and IV Therapy: What We Know

The short answer

NAD+ injections and IV infusions deliver the NAD+ molecule itself, which is something no oral product can reliably do. They are the established clinical route for NAD+, with decades of use in addiction medicine and a published human pharmacokinetic study showing that infused NAD+ is taken up from the blood quickly. What they do not have is a completed randomized controlled trial showing a benefit for any of the things clinics advertise them for: energy, cognition, recovery, addiction withdrawal, or aging. The evidence is real but thin, the infusion reactions are real and common, the products are compounded rather than FDA-approved, and the cost is substantial. This article explains what is known. It does not provide doses or protocols; injected NAD+ is a clinical decision made with a prescriber.

Why inject NAD+ at all

NAD+ taken by mouth is not effectively absorbed. It is a large, charged molecule that the intestine and liver break down into nicotinamide and other fragments before it can reach the bloodstream intact, which is why the oral market is built on precursors (NMN and nicotinamide riboside) rather than on NAD+ itself. Liposomal oral NAD+ is being researched and its absorption is unclear; nasal sprays and patches have no human data, as covered in NAD+ nasal spray, patches and liposomal NAD+.

Injection skips all of that. Intravenous infusion places NAD+ directly in the blood; subcutaneous injection deposits it under the skin for slower uptake. These are the two routes with clinical use and research behind them for delivering NAD+ as NAD+. The background on the molecule, and on what raising it is supposed to achieve, is in the NAD+ pillar.

Where this came from

Injected NAD+ is not a new wellness invention. In 1961 a physician named Paul O’Hollaren published a report describing intravenous NAD+ (then called diphosphopyridine nucleotide, or DPN) given to patients withdrawing from alcohol and narcotics, claiming reduced craving and withdrawal symptoms in a large case series. That work was uncontrolled and was not followed by a trial, but it seeded a tradition of IV NAD+ in addiction treatment that persisted quietly in a handful of clinics for decades, mostly in the United States and South Africa. The modern wellness market grew out of that tradition in the 2010s, as NAD+ became a longevity research target and clinics broadened the offer from detox to energy, cognition and anti-aging.

What the research actually shows

Pharmacokinetics

The single most informative human study is a 2019 pilot from Grant and colleagues, who gave eleven healthy men a slow six-hour intravenous infusion of NAD+ and sampled blood and urine throughout. The finding that surprised the field was that plasma NAD+ did not rise at all for the first two hours of the infusion, even though NAD+ was being delivered continuously. Levels of NAD+ metabolites rose in urine during the same window, and plasma NAD+ climbed only later in the infusion. The authors’ interpretation was that infused NAD+ is rapidly taken up by tissues or broken down and rebuilt, rather than accumulating in the blood, and that the infusion was well tolerated at the rate used.

⚠ CLAIM (wellness): In a pilot study of eleven healthy men, intravenous NAD+ infused over six hours was rapidly cleared from plasma during the first two hours, with NAD+ metabolites rising in urine, and plasma NAD+ increasing only later in the infusion. The infusion was well tolerated. This is a pharmacokinetic study in a small sample; it did not measure any clinical outcome. Basis: Grant 2019 Front Aging Neurosci. Lane: educational.

That study establishes that infused NAD+ goes somewhere fast. It does not establish where, whether it raises NAD+ inside cells that need it, or whether that produces any benefit. It also does not cover subcutaneous injection, which has no published human pharmacokinetic study.

Clinical outcomes

For every indication clinics advertise, the evidence is at the case-series and open-label level or below.

Advertised use	Best available human evidence	Quality
Alcohol and drug withdrawal	O’Hollaren 1961 case series; modern clinic reports; small open-label observations	Uncontrolled; no RCT
Chronic fatigue	Anecdotal; one small oral NADH trial from the 1990s, not IV	No IV data
Cognition, brain fog	Precursor trials (NR) show brain NAD+ can rise; no IV NAD+ cognition trial	No IV data
Athletic recovery	Anecdotal	None
Anti-aging, longevity	Mechanistic and animal work on NAD+; no human outcome trial by any route	None
Long COVID	Case reports; precursor trials in progress	No IV data

⚠ CLAIM (wellness): No completed randomized controlled trial has shown that intravenous or subcutaneous NAD+ improves any clinical outcome. Claims of benefit for withdrawal, fatigue, cognition, recovery or aging rest on case series, open-label reports and anecdote. Basis: literature review as of 2026; O’Hollaren 1961; Braidy 2019 review. Lane: educational.

This is the part that clinic websites tend to leave out. “Backed by research” is true of the biochemistry of NAD+ and of the pharmacokinetics of infusing it. It is not true of the outcomes.

Side effects and infusion reactions

Infusion reactions are the defining side effect of IV NAD+, and they are common enough that managing them is part of how every clinic runs the drip. The published pharmacokinetic study reported good tolerability at its slow rate, and the consistent clinical and community picture is that reactions are rate-dependent: faster infusions produce more of them.

• Chest tightness or pressure, sometimes described as feeling like the chest is being squeezed. The most alarming reaction and usually the reason a drip gets slowed or paused.
• Flushing and warmth, particularly in the face and upper body.
• Nausea, occasionally vomiting.
• Abdominal cramping, which can be severe during a fast infusion.
• Headache, often described as pressure behind the eyes.
• Anxiety or a sense of dread during the infusion, which resolves when it is slowed.
• Muscle cramps, fatigue, and lightheadedness.

The mechanism is not established. Proposed explanations include rapid NAD+ breakdown to nicotinamide and adenosine-related compounds, with adenosine in particular being a plausible cause of chest pressure and flushing, but this has not been tested directly. Subcutaneous injections avoid the infusion-rate problem and are reported to cause injection-site pain, redness and swelling, with flushing and nausea less often. The oral precursors have a far milder profile, covered in NAD+ supplement side effects.

Because no controlled trial has been done, there is no reliable estimate of how often serious reactions occur, and no long-term safety data. The same open question that applies to oral precursors applies here with more force: nobody knows what raising NAD+ does to an existing tumor, preclinical evidence points both ways, and an infusion delivers far more NAD+ far faster than a capsule. A current or recent cancer diagnosis is a reason to raise this with an oncologist before booking.

Regulatory status

NAD+ for injection is not an FDA-approved drug for any indication. It is supplied by compounding pharmacies, which prepare it on prescription, and the quality controls vary with the pharmacy. Clinics offering it are practicing medicine, usually under a physician or nurse practitioner, and the product should come with the pharmacy’s certificate of analysis showing identity, sterility and endotoxin testing. Home subcutaneous kits sold through telehealth follow the same model. Anything sold for injection without a prescription and a named compounding pharmacy is outside that system and should be treated accordingly; NAD+ in solution is also unstable, so an unrefrigerated vial of uncertain age may contain little NAD+.

What people report

Anecdotal experience, clearly separated from the evidence above. Community accounts of IV NAD+ are unusually polarized and none of them is evidence of an effect.

• A common positive report is several days of unusual energy and mental clarity after an infusion, sometimes described as the best they have felt in years. Some people repeat infusions monthly on the strength of it. No controlled comparison exists, and the expectation, the clinic setting, and the hydration from a multi-hour drip are all plausible contributors.
• An equally common report is that the infusion itself was miserable: hours of chest pressure, cramping and nausea, sometimes with the drip repeatedly paused, followed by nothing they could attribute to it afterward.
• In addiction recovery communities, NAD+ infusions have a devoted following for easing withdrawal, and an equally vocal set of people who found them expensive and ineffective. The clinic literature is enthusiastic and uncontrolled.
• Subcutaneous users describe a gentler, less dramatic experience, with mild energy effects and injection-site soreness, and a fair number report nothing at all.
• Cost is a recurring theme. Infusions are priced in the hundreds of dollars per session, and the people most satisfied tend to be those who went in with a specific complaint rather than a general hope.

How to think about it

Injected NAD+ is the one route that unambiguously delivers the molecule, and that is worth something if you have a specific reason to want NAD+ rather than a precursor. It is also a clinical procedure with common, sometimes intense infusion reactions, no outcome trials, a compounded product, and a price that buys a great deal of NMN. If you are considering it, the questions worth asking a clinic are which compounding pharmacy supplies the product, whether a certificate of analysis is available, how the infusion rate is managed, what the plan is if a reaction occurs, and what specific outcome they expect for you and on what evidence. A clinic that answers the last one with “research shows” and cannot name the study is telling you something.

Educational information only, not medical advice, and not evaluated by the FDA. NAD+ injections and infusions are compounded, prescription-only clinical procedures that are not FDA-approved for any indication, and this article intentionally provides no doses, rates or protocols. NAD+ is not a treatment for any disease. Talk to a clinician before considering injected NAD+ if you have a current or previous cancer diagnosis, heart disease, take prescription medication, or are pregnant or breastfeeding.